Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYM Form 4 May 22, 200	E THERAPEUT	ICS INC	-								
									OMB APPROVAL		
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSI Washington, D.C. 20549						OMMISSION	OMB Number:	3235-0287		
Check th if no long subject to Section 1 Form 4 of Form 5 obligatio may com See Instr	Section 1 Public U	IGES IN SECUI 6(a) of th tility Hol westmen	Expires: January 31, 2005 Estimated average burden hours per response 0.5								
1(b). (Print or Type l	Responses)										
1. Name and Address of Reporting Person * 2. Iss Kelley Kenneth J Symbol HALC					d Ticker or HERAPE			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Month				e of Earliest Transaction n/Day/Year) /2007				X_ Director 10% Owner Officer (give title Other (specify below) below)			
				nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SAN DIEG	O, CA 92121							Form filed by M Person			
(City)	(State)	(Zip)	Tabl	le I - Non-J	Derivative	Secur	rities Acau	uired, Disposed of,	or Beneficiall	v Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executior any	med 3. on Date, if Transactior Code Day/Year) (Instr. 8)		4. Securities Acquired ior(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	05/18/2007			Code V $S_{(1)}^{(1)}$	Amount 8,800	(D) D	Price \$ 10.55	21,200	D		
Common Stock	05/18/2007			S <u>(1)</u>	4,800	D	\$ 10.556	16,400	D		
Common Stock	05/18/2007			S <u>(1)</u>	1,400	D	\$ 10.56	15,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Amou Under Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Kelley Kenneth J C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CA 92121

Signatures

/s/ Kenneth J. Kelley	05/21/2007				
<u>**</u> Signature of Reporting Person	Date				

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares purchased and sold, as applicable, under 10b5-1 plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Director 10% Owner Officer Other

Relationships

Х